Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1-based Adjuvant Therapy in High-risk Hepatocellular Carcinoma Patients After Curative Resection

NCT05307926 is registered in ClinicalTrials.gov with Chen Xiaoping as lead sponsor.

NCT NCT05307926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05307926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1-based Adjuvant Therapy in High-risk Hepatocellular Carcinoma Patients After Curative Resection
Lead sponsor
Chen Xiaoping
Phase
Observational
Overall status
Completed
Start date
February 1, 2019
Completion date
August 20, 2022
Enrollment
573 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, rfs